Locate Available Clinical Trials

To view available Clinical Trial information choose from the list on the right or search using the fields below.



trial #
trial description
  • CALGB 50801
  • This research is being done in order to improve treatment outcomes in patients diagnosed with bulky, early stage Hodgkin lymphoma and to reduce the side effects that are associated with use of radiation used in current treatments. The chemotherapy treatment in this study consists of a combination of four drugs approved by the Food and Drug Administration (called FDA): doxorubicin, bleomycin, vinblastine, and dacarbazine. This regimen (called ABVD) has been found to be effective in treating patients with Hodgkin lymphoma and is considered the standard of treatment used with radiation therapy in patients with bulky early stage Hodgkin lymphoma. Radiation therapy has been sometimes associated with late side effects including second cancers, and damage to organs including blood vessels, muscles, heart, and lungs. As part of the evaluation of the effectiveness of the chemotherapy treatment, PET scans will be obtained during the course of your treatment. We will evaluate the usefulness of this PET scan to determine whether radiation may be left out in the treatment of your disease if the PET scan shows you have responded to chemotherapy alone. Although most patients with this stage of Hodgkin lymphoma are probably cured with ABVD chemotherapy alone, there is a suggestion from the literature that patients who have PET scans that are positive during chemotherapy may have a decreased chance of cure. For this reason chemotherapy may be given that is stronger than ABVD and adding radiation therapy if the PET scan is positive after 2 cycles of ABVD chemotherapy.

  • SWOG S1001
  • Limited (or early) stage diffuse large B-cell lymphoma is curable in many people, but some still relapse, and some develop side effects after treatment. This study uses a test called PET/CT scan to determine treatment after initial doses of a standard chemotherapy called "R-CHOP" (This is the drugs: doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab). Although all of the drugs used in this study are approved by the Food and Drug Administration (called FDA), the purpose of the study is to give more intensive treatment to patients whose PET/CT scan shows that they are at a greater chance of still having active lymphoma, and to give less intensive treatment to patients whose PET/CT scan shows that they have a smaller chance of still having active lymphoma. In this way, we hope to improve the cure rate for all patients while decreasing the side effects of the treatment.